Shire orders limited recall of Daytrana patch

UK drugmaker Shire is undertaking a voluntary market withdrawal of a limited portion of its Daytrana (methylphenidate transdermal system product. Shire is taking this action primarily due to feedback from patients and caregivers who have experienced difficulty removing the release liner from some Daytrana patches. Based on preliminary information, the retail value of product being withdrawn is estimated to be in the $4.0 million to $6.0 million range.

In the first quarter of 2007, Shire and the agent's US originator, USA-based Noven, implemented enhancements to the Daytrana release liner intended to improve ease of use of the patch, and product using the enhanced release liner is now in the trade channels. The firms say they are committed to improving the ease of use of Daytrana so patients can use its with the convenience they expect from this novel attention-deficit hyperactivity disorder treatment option.